Effect of Two Different Modes of Polarized Polychromatic Non-coherent Light Therapy on Jumper's Knee

May 16, 2026 updated by: Mahmoud Shahien, Cairo University

The purposes of this study are:

  1. To examine the combined effects of Yellow CPPNLT and conventional treatment on pain intensity, pain pressure threshold, functional disability, and muscle strength in athletic jumper knee.
  2. To examine the combined effects of Green CPPNLT and conventional treatment on pain intensity, pain pressure threshold, functional disability, and muscle strength in athletic jumper knee.

3 3- To compare between the effects of Yellow CPPNLT and Green CPPNLT on pain intensity, pain pressure threshold, functional disability, and muscle strength in athletic jumper knee.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Jumper's knee is an overuse injury of the tendon that alters the knee due to repeated stress of activities. Symptoms include pain in the front of the knee. The tears are typically caused by accumulated stress on the patellar or quadriceps tendon. As the name implies, the condition is common in athletes from jumping sports, where there is a high demand for the speed and power of leg extensors. These sports often lead to high eccentric quadriceps loadings, such as volleyball, track (long and high jump), basketball, long-distance running, and skiing. The prevalence of jumper knee is not well examined so far. For non-elite adult athletes the prevalence varies between 14.4% and 2.5% for different sports.Only 2.4% of adolescent professional soccer players sustain PT. However, knee pain, focal tenderness or even acute episodes of PT have a major impact on each player's development, time off the pitch, and career.Bioptron was used for treatment of arthritis, neck&back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasm. There are some studies that have discussed the extent of the effect of the Bioptron Light Therapy on musculoskeletal disorders such as; rotator cuff tendinitis, tennis elbow, carpal tunnel syndrome, acute patellar tendinopathy and acute ankle sprain. There is a lack of the evidence of the clinical guidelines of patellar tendinitis. Up to our knowledge, there is no clear recommendation about efficiency of different colors of Bioptron light therapy on jumper knee. So; this study will be conducted to determine efficiency of yellow and green colors of polychromatic non-coherent light. Sixty subjects will participate in this study and will be divided randomly into three equal groups.Group A (Study group): Will receive green filter of bioptron light therapy and conventional treatment for jumper knee,group B (Study group): Will receive yellow filter of bioptron light therapy and conventional treatment for jumper knee and group C (Control group): Will receive conventional treatment (ice application+ exercise program) for jumper knee.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Dokki
      • Giza, Dokki, Egypt, 12612
        • Physical Therapy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • History of Patellar tendinitis and anterior knee pain.
  • Age will be ranged from 15 to 35 years.
  • Both genders.
  • The onset of pain for over 3 months.

Exclusion Criteria:

  • Knee surgery within the previous 6 months.
  • Chronic joint diseases.
  • Corticosteroid injection in the patellar tendon within the previous 3 months.
  • Use of drugs 48 hours previously (e.g., NSAIDs).
  • Any other concomitant treatment for PT.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Group A
the patients will receive green filter of bioptron light therapy and conventional treatment((ice application+ exercise program)) for jumper knee three times a week for four weeks.
Device: Bioptron
Bioptron safely treats arthritis, neck & back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
Other Names:
  • Polarized Polychromatic Non-Coherent Light
  • Hyperlight
Experimental: Group B
the patients will receive yellow filter of bioptron light therapy and conventional treatment for jumper knee three times a week for four weeks.
Device: Bioptron
Bioptron safely treats arthritis, neck & back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
Other Names:
  • Polarized Polychromatic Non-Coherent Light
  • Hyperlight
Placebo Comparator: Control group
the patients will receive conventional treatment (ice application+ exercise program) for jumper knee three times a week for four weeks.
Other: Placebo Comparator
Patients will receive ice application+Exercises program designed for jumper knee

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Pain (Visual analogue scale).
Time Frame: Visual analogue scale will be investigated at baseline and after the treatment period of 4 weeks.
The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. The VAS score for grading of pain consists of a 10 centimeters (cm) line with 10 mm (0.01 cm) to each point of the scale and two end-points representing no pain and worst possible pain.
Visual analogue scale will be investigated at baseline and after the treatment period of 4 weeks.
pain intensity (Pressure algometry)
Time Frame: Pressure algometry will be investigated at baseline and after the treatment period of 4 weeks.
Pressure pain threshold will be measured with algometry test FPX25 using 1-cm2 rubber tip on the knee extensors.10, 11 pressures will be applied slowly until the participant first feels the pain and response by saying stop there.
Pressure algometry will be investigated at baseline and after the treatment period of 4 weeks.
Disability questionnaire (Victorian institute of sport assessment-patella).
Time Frame: The VISA-P questionnaire will be investigated at baseline and after the treatment period of 4 weeks.
The VISA-P, formerly known as the Victorian institute of sport assessment -patella Questionnaire, The VISA-P is questionnaire that assesses symptoms, simple tests of function, and the ability to play sports.
The VISA-P questionnaire will be investigated at baseline and after the treatment period of 4 weeks.
Muscle strength (Lafayette Hand held dynamometer)
Time Frame: The Lafayette hand held dynamometer will be investigated at baseline and after the treatment period of 4 weeks.
The subjects will be positioned in sitting on chair and we will apply resistance when performing the dynamometer on patients and they will try to make maximal effort against resistance and we will record the change of length or resistance.
The Lafayette hand held dynamometer will be investigated at baseline and after the treatment period of 4 weeks.

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Muscle strength and endurance ( Isoforce tur-Isokinetic Dynamometer)
Time Frame: The Isokinetic dynamometer will be investigated at baseline and after the treatment period of 4 weeks.
The subjects will be positioned in sitting on isokinetic chair and we will ask the subjects to perform maximal knee extension and we will record the change of muscle power or endurance
The Isokinetic dynamometer will be investigated at baseline and after the treatment period of 4 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cairo University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Adel R Ahmed, PHD, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 29, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 25, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 10, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 12, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 19, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 16, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • PT.REC/012/004881

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings